Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07226661
Title field or adapter rule
{'original_value': 'A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:37.337288+00:00
Published At
2026-10-28T00:00:00+00:00
Record Updated At
2026-10-28
Source Retrieved At
2026-10-31T22:19:07.580396+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Major Depressive Disorder (MDD)"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-28", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT07226661"
protocolSection.identificationModule.officialTitle
"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Major Depressive Disorder (MDD) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['SPN-821 2400 mg'], 'description': 'SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling', 'name': 'SPN-821 2400 mg', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Placebo'], 'description': 'Matched placebo oral tablets', 'name': 'Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • SPN-821 2400 mg (protocolSection.armsInterventionsModule.interventions[].name)
  • Placebo (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.